Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

Altimmune Inc. (NASDAQ:ALT) saw its stock tumble by 37% after releasing topline data from its Phase 2b IMPACT trial ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

From the outset, the cast of the television series MASH was a solid ensemble of performers, led by Alan Alda, who ...

Michter’s 2025 Legacy Series features two limited releases: Bomberger’s Declaration Kentucky Straight Bourbon (54% ABV) and ...

With his home run in Thursday’s 3-1 victory over the Rockies, Ohtani became one of only three Dodgers’ hitters to mash 28 ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

From more draught lines in pubs to more experimental non-alcoholic beers, the no and low space has changed significantly over the past five years.

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis ...

FOX21 Storm Team Meteorologist Robert Hahn took the Storm Squatch on the road to Downtown Colorado Springs to visit with ...

Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...

Bathed in golden-hour light, the BeltLine, a pedestrian thoroughfare in Atlanta, had an enchanting atmosphere on the Thursday ...